fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Nitrofurantoin

All products: general benefit

Nitrofurantoin · DIN 00312738 · 100 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Nitrofurantoin · DIN 00312738 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Daily cost (source): $0.9088 Health Canada: Marketed since 2011-10-25 · brand NITROFURANTOIN · ATC J01XE01 NITROFURANTOIN · form Tablet · route Oral · ingredients NITROFURANTOIN 100 MG · company Aa pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Nitrofurantoin: Formulary list price $0.23 per unit (the source does not state the unit; exact figure $0.2272). What the ministry pays, not the patient.

Ministry pays: $0.2272 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00312738)

Source record
DIN 00312738: Nitrofurantoin Raw flags: sec3=Y Item: 083600008; group id 127; item number 0215; lccId None; manufacturer id AAP Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.2272; ministry $0.2272 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00312738 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2093
Interchangeable products
Nifuran · DIN 00017094 · not recorded
Shortage status: resolved shortage (ended March 11, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00312738
Shortage record checked October 6, 2026

Other products in the same Health Canada class (J01X, J01XE): coverage varies; not interchangeable

  • Micro crystals + nitrofurantoin mono (MacroBID): general benefit, not a benefit
  • Fosfomycin tromethamine (Monurol): general benefit
Other drugs in the same formulary class (08:36 Urinary Anti-Infectives) and how they are covered

Matched class: 08:36 Urinary Anti-Infectives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: FOSFOMYCIN TROMETHAMINE Some products covered without a code (check the product listing): NITROFURANTOIN MONO/MICRO CRYSTALS 08:36 Urinary Anti-Infectives

NITROFURANTOIN MONO/MICRO CRYSTALS

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 100mg · Cap

FOSFOMYCIN TROMETHAMINE

· 2 products · General benefit · strengths: · Sachet-3g Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:36
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:18 Antivirals, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 Indications NITROFURANTOIN (Nitrofurantoin tablets) is indicated for:  The treatment of pyelonephritis, pyelitis, and cystitis when due to susceptible organisms. NITROFURANTOIN is not for the treatment of associated renal cortical or perinephric abscesses, nor in prostatitis. To reduce the development of drug-resistant bacteria and maintain the effectiveness of NITROFURANTOIN and other antibacterial drugs, NITROFURANTOIN should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. 1.1 Pediatrics Pediatrics (< 1 month of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of NITROFURANTOIN in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use. See 2 Contraindications. 1.2 Geriatrics Geriatrics (>65 years of age): Evidence from clinical st… https://pdf.hres.ca/dpd_pm/00080984.PDF PM date: 2025-07-03 Source product: NITROFURANTOIN; DIN 00312738; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.